Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis

• Status: Unknown status
• Trial end date: 2015-11-01

Summary

The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes.

The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.

• Phase: Phase 3

Details

• Lead Sponsor: Fundación Pública Andaluza Progreso y Salud
• Collaborator: Instituto de Salud Carlos III
• Treatments: Amisulpride; Antipsychotic Agents; Aripiprazole; Asenapine; Chlorpromazine; Clopenthixol; Clothiapine; Clozapine; Droperidol; Flupenthixol; Flupenthixol decanoate; Haloperidol; Haloperidol decanoate; Methotrimeprazine; Olanzapine; Paliperidone Palmitate; Perphenazine; Pimozide; Quetiapine Fumarate; Risperidone; Sertindole; Sulpiride; Sultopride; Tiapride Hydrochloride; Trifluoperazine; Ziprasidone